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MYCBP2 is a ubiquitin (Ub) E3 ligase (E3) that is essential for neurodevelopment and 3 
regulates axon maintenance. MYCBP2 transfers Ub to non-lysine substrates via a newly 4 
discovered RING-Cys-Relay (RCR) mechanism where Ub is relayed from an upstream 5 
cysteine to a downstream substrate esterification site. The molecular bases for E2-E3 Ub 6 
transfer and Ub relay are unknown. Whether these activities are linked to the neural phenotypes 7 
is also unclear. We describe the crystal structure of a covalently trapped E2-Ub:MYCBP2 8 
transfer intermediate revealing key structural rearrangements upon E2-E3 Ub transfer and Ub 9 
relay. Our data suggest that transfer to the dynamic upstream cysteine, whilst mitigating lysine 10 
activity, requires a closed-like E2-Ub conjugate with tempered reactivity, and Ub relay is 11 
facilitated by a helix-coil transition. Furthermore, neurodevelopmental defects and delayed 12 
injury-induced degeneration in RCR-defective knock-in mice suggest its requirement, and that 13 
of substrate esterification activity, for normal neural development and programmed axon 14 
degeneration.  15 
 16 
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 18 
  19 
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Main 1 
Ubiquitination is a post-translational modification that regulates all aspects of 2 
eukaryotic biology1. Ubiquitin (Ub) transfer is initiated by an ATP-dependent Ub-activating 3 
enzyme (E1). Ub is transferred from E1 to the catalytic cysteine of a ubiquitin-conjugating 4 
enzyme (E2) via a chemical reaction known as transthiolation. The thioester-linked 5 
intermediate (E2~Ub) is recruited by one of hundreds of ubiquitin E3 ligases (E3s), which 6 
mediate discharge of Ub to specific substrates2. Four distinct classes of E3 have been identified 7 
but as our current understanding of E3 mechanism is based on a small subset of members, their 8 
true diversity is likely to be unappreciated. The largest classification corresponds to RING/U-9 
Box E3s (referred to hereafter as RING E3s)3. RING E3s use an adaptor-like mechanism to 10 
recruit the conformationally malleable E2~Ub conjugate4. RING E3s induce a folded back or 11 
“closed” E2~Ub conformation which immobilizes the thioester, allosterically configures the 12 
E2 active site for catalysis, and is a requisite for efficient aminolysis of a lysine acceptor5-9. 13 
Maintenance of the closed conformation involves a network of interactions between E2 and 14 
Ub. Activated RING E3 binding stabilizes these interactions thereby catalyzing substrate 15 
ubiquitination7-9. In contrast, HECT and RBR E3 classes, that possess an essential catalytic 16 
cysteine, undergo transthiolation with E2~Ub forming a covalent intermediate10,11. Consistent 17 
with the increased nucleophilicity of cysteine relative to lysine, HECT/RBR E3s engage 18 
E2~Ub in a non-activating, “open” conformation9,12-16. E3s that undergo transthiolation must 19 
prevent inadvertent aminolysis activity and current experimental evidence supports the notion 20 
that HECT/RBR E3s achieve this by enforcing the open conformation12,15,16. These 21 
observations imply that induction of the closed E2~Ub conformation is a specialised catalytic 22 
feature reserved for adaptor-like E3 transfer to lysine acceptors and open conformations are 23 
specialised, and sufficient, for transthiolation with cysteine.  24 
MYCBP2 (also known as Phr1 (PAM-Highwire-Rpm-1)) is a conserved 0.5 MDa E3 25 
with important roles in synaptogenesis and axon termination17-22. MYCBP2 has also been 26 
shown to ubiquitinate Fbxw7 and ULK1 kinase thereby promoting chemotherapy resistance 27 
and inhibiting neuronal autophagy, respectively23,24. MYCBP2 was found to possess a novel 28 
class of cysteine-dependent E3 machinery we termed RING-Cys-Relay (RCR)25. Constitutive 29 
Phr1-/- mice (murine ortholog of MYCBP2) present with compromised axon development and 30 
the phrenic nerve fails to fully innervate the diaphragm leading to perinatal respiratory failure26. 31 
However, conditional silencing of Phr1 in adult mice is tolerated and confers potent axon 32 
protection in vivo and in in vitro primary neuron culture models of axon degeneration after 33 
physical injury (Wallerian degeneration), or administration of the chemotherapeutic agent 34 
 4 
vincristine27. Thus, MYCBP2 is likely to have distinct roles in neural development and axon 1 
maintenance. Due to its latter role it has become a potential therapeutic target for a range of 2 
neurological conditions and neurodegenerative diseases28.  3 
The MYCBP2 RCR machinery utilises a RING domain that is presumed to bind E225,29. 4 
However, the RING domain is linked to a Tandem Cysteine (TC) domain containing two 5 
catalytic cysteine residues25. The upstream cysteine undergoes transthiolation with E2~Ub and 6 
a subsequent step, termed Ub relay, shuttles Ub to the downstream cysteine by means of 7 
intramolecular transthiolation. The downstream site has esterification activity with selectivity 8 
for threonine25. A crystal structure of the RCR machinery has revealed the general architecture 9 
of the TC domain and the basis for threonine-esterification activity25. However, neither an 10 
E2~Ub:RCR transfer complex nor the upstream catalytic site (referred to as the mediator loop) 11 
have been structurally resolved. Thus, the molecular bases for E2~Ub recruitment, E2-E3 12 
transthiolation and Ub relay are unknown. Furthermore, it remains unknown if loss of 13 
MYCBP2’s unusual RING-linked RCR mechanism (i.e. E2-E3 transthiolation followed by Ub 14 
relay, and substrate esterification), is central to the neurodevelopmental and axon protective 15 
phenotypes.  16 
 Here we use a chemically engineered E2~Ub conjugate as a suicide substrate25,30, which 17 
permits chemical stabilization of the dynamic mediator loop and the otherwise transient 18 
tetrahedral E2~Ub:RCR transfer intermediate. We solve the crystal structure of this transfer 19 
complex which reveals that MYCBP2 seemingly employs a distinct form of the closed E2~Ub 20 
conjugate associated with an attenuated state of thioester activation. Our data suggest this 21 
compensates for the dynamic nature of the upstream MYCBP2 catalytic cysteine whilst 22 
mitigating lysine activity. The structure also reveals novel RING-E2 recognition elements and 23 
insights into the unexpected incompatibility with a cysteine-reactive E2. We find the mediator 24 
loop region, disordered in the apo structure, adopts a short a-helix upon E2-E3 transthiolation. 25 
Surprisingly, mutational analysis of the mediator loop reveals that both E2-E3 transthiolation 26 
and Ub relay are highly robust processes. However, whilst helix disrupting proline mutations 27 
in general do not affect E2-E3 transthiolation, they impair Ub relay. This suggests that transient 28 
helix formation is requisite for Ub relay, which we propose is mediated by an entropically-29 
driven helix-coil transition. To assess whether loss of RCR E3 activity is linked to the neural 30 
phenotypes we generate upstream cysteine mutant (Phr1C4629A/C4629A) mice where E2-E3 31 
transthiolation, subsequent relay, and substrate esterification activity are abolished. 32 
Remarkably, we find that the neurodevelopmental and axon protective phenotypes presented 33 
 5 
in null animals are recapitulated in Phr1C4629A/C4629A mouse neurons indicating that loss of 1 





Structure determination of the E2-E3 transfer intermediate 7 
 8 
Although chemical engineering approaches have been instrumental for the stabilization 9 
and structural resolution of the conformationally dynamic transfer intermediates associated 10 
with Ub conjugation31-33, structural resolution of a tetrahedral, enzymatic ubiquitin-acyl donor 11 
intermediate has not been reported for any E3 classification. A previously described activity-12 
based probe (ABP) based on a chemically engineered E2~Ub conjugate, functions as a suicide 13 
substrate for E3 transthiolation25,30 (Fig. 1a, b). We used this ABP to covalently modify the 14 
RCR, enabling stabilization of the dynamic mediator loop and the transient E2-E3 Ub transfer 15 
complex (Fig. 1b). Importantly, ABP E3 catalytic cysteine labelling forms a tetrahedral 16 
bisthioether that locally recapitulates the geometry of the anticipated tetrahedral Ub 17 
transthiolation intermediate (Fig. 1b). Diffracting crystals of the engineered covalent 18 
E2~Ub:RCR complex were obtained and a structural model was refined to 2.58 Å (Fig. 1c–e 19 
and Extended Data Figs. 1–3).  20 
 21 
The RCR E3 engages a closed-like E2~Ub conformation  22 
 23 
Our structure accurately recapitulates a transition state intermediate for Ub transfer 24 
from E2 to the upstream Cys4520 residue within the E3 mediator loop. The mediator loop is 25 
now found to be structured and forms a short a-helix (Fig. 1d, e). Mediator loop residues do 26 
not appear to catalytically participate in the transfer process. Rather, transfer to the upstream 27 
cysteine residue is facilitated by the RCR binding E2~Ub in a closed conformation, which is 28 
entirely distinct from reported catalytic-cysteine dependent E3s12,13,15,16. However, a ~30° 29 
rotation of the Ub molecule, centering on Ub Ile44, alters the closed E2~Ub conformation (Fig. 30 
2a). Rotation maintains the highly conserved Ub Ile44 interaction with E2 crossover helix 31 
residue Leu1045,6, which is dispensable for HECT/RBR activity9. Other interactions with the 32 
globular Ub fold, previously identified as essential for canonical ‘closed’ E2~Ub activation to 33 
 6 
lysine acceptors, are also largely maintained in the RCR:E2~Ub complex (Fig. 2b, 2c, 1 
Extended Data Fig. 4-5). There are two notable exceptions. Firstly, an interaction between Ub 2 
Ile36 and the RING domain is lost (Extended Data Fig. 4b). Typically, alanine mutation at this 3 
site abolishes canonical activity7,8. Consistent with this interaction being dispensable for 4 
activity, a Ub I36A mutant only decreases RCR activity by ~50 % (Fig. 2c). Partial dependence 5 
might be reconciled by an intramolecular Ile36 side chain interaction with Leu71 in the Ub tail 6 
(Extended Data Fig. 5a). Secondly, the RCR complex lacks the so-called “linchpin” 7 
interactions between a conserved arginine/lysine residue within the RING domain9. 8 
Prototypical RING/E2~Ub complexes have this residue forming bivalent hydrogen-bonds 9 
between E2 Gln92, Ub Gln40 and Ub Arg72 (Extended Data Fig. 4b)7-9. These interactions 10 
contribute to anchoring the carboxy terminus of Ub into the E2 active site groove and are 11 
considered important for optimum thioester immobilization and E2 active site configuration as 12 
their disruption leads to undetectable/negligible activity7-9. In the RCR complex the Ub rotation 13 
shifts Ub Arg72 ~12 Å away from linchpin Lys4441, abolishing its interaction with the E2 14 
Gln92 backbone and Ub Gln40 (Extended Data Fig. 4b). Consistent with a relaxed role, activity 15 
of an RCR Lys4441Ala mutant was reduced only by 40 % and a Ub Gln40Ala mutant was 16 
unaffected (Fig. 2c)7. A presumed consequence of the lack of these two key canonical 17 
interactions would be an intermediate state of thioester activation relative to previously 18 
reported RING exemplars. 19 
 20 
Ubiquitin transfer to the RCR requires E2~Ub activation 21 
 22 
As our structure geometrically recapitulates a covalently trapped E2~Ub acyl donor 23 
intermediate, the orientation of active site residues during catalysis can be inferred (Fig. 2d, 24 
Extended Data Fig. 4b). We find that as previously proposed for closed E2~Ub activation, 25 
catalysis hinges on E2 Asn77. Canonical closed E2~Ub activation leads to an active site 26 
configuration that brings the essential Asn77 residue into proximity of the thioester carbonyl 27 
oxygen atom in E2~Ub7,11,34,35. Here, Asn77 might catalytically activate E2~Ub to lysine 28 
nucleophilic attack by stabilizing the transient negative charge that forms on the thioester-29 
derived oxygen atom in the tetrahedral transfer intermediate. Alternately, Asn77 may act 30 
indirectly by hydrogen bonding to the backbone of Asn114 and stabilize the E2 active-site loop 31 
containing Asp117 (Fig. 2d)36,37. A role in thioester immobilization has also been proposed38. 32 
As Asn77 is dispensable for HECT/RBR activity it is thought these requirements are a hallmark 33 
of a closed E2~Ub activation mechanism for lysine acceptors11,13.  34 
 7 
Consistent with our complex, the dependence on Asn77 for RCR activity underscores 1 
the unexpected requirement for closed-like E2~Ub activation for transthiolation with MYCBP2 2 
(Fig. 2c). In our transthiolation complex, Asn77 is geometrically compatible with stabilizing 3 
the transient negative charge on the thioester-derived oxygen atom, yet we also observe the 4 
interaction between Asn77 and the backbone of Asn114 (Fig. 2d, Extended Data Fig. 4-5). 5 
Hence, to elucidate if Asn77 has a particular role in E2-MYCBP2 Ub transfer we determined 6 
observed rate constants for Asn77Ser, Asn114Ala, Asp117Ala, and a Asn114Ala Asp117Ala 7 
double mutant (Extended Data Fig. 4e-i). In addition to kinetically quantifying the mutants in 8 
single turnover C4520K isopeptide assays, we also assessed native cysteine transthiolation 9 
activity, thereby allowing potential acceptor-specific roles to be uncovered (Extended Data 10 
Fig. 4i, 5e-i)). Strikingly, the observed rates for native transthiolation for Asp117Ala and the 11 
Asn114Ala Asp117Ala double mutant were indistinguishable from WT E2, indicative of the 12 
described structural role of Asn77 being dispensable. However, the Asn77Ser mutant had no 13 
detectable activity (Extended Data Fig. 4i, 5f). This suggests that Asn77’s role in MYCBP2 14 
transthiolation is tetrahedral intermediate stabilization and/or thioester immobilization; both of 15 
which are consistent with our structure (Fig. 2d). In contrast, in the isopeptide assay lysine 16 
aminolysis was undetectable upon mutation of Asp117, demonstrating that its role is likely to 17 
be specific for lysine acceptors where its has been shown  to position the lysine e-amino group 18 
and/or suppress its pKa35,37,38. Consistent with interactions towards the Asn114 backbone being 19 
key7,36, Asn114Ala rates were comparable to WT. However, our data cannot exclude the 20 
possibility that alternative structural roles mediated by Asn77 may facilitate lysine 21 
aminolysis36. 22 
Independent of Asn77, E2 Asp87 augments the canonical linchpin interaction by further 23 
anchoring the Ub C-terminus by interaction with Ub Arg74. This interaction was thought to 24 
only be required for lysine acceptors7,8,11. We find this interaction also remains critical further 25 
underscoring the unusual closed-like requirement for MYCBP2 transthiolation with E2 (Fig. 26 
2c, d, Extended Data Fig. 4d).  27 
 28 
E2~Ub activation compensates for mediator loop entropy 29 
  30 
An explanation for why transfer to cysteine in the context of the RCR requires E2~Ub 31 
activation whereas HECT/RBR E3s do not is that whilst the dynamic nature of the upstream 32 
cysteine will not affect intrinsic sulfhydryl reactivity, it might compromise its ability to serve 33 
 8 
as an effective nucleophile39. The lack of the linchpin and Ub Ile36 interactions would be 1 
expected to compromise the stability of the closed conformation that catalytically configures 2 
the active site. In turn, this would attenuate thioester reactivity. However, as MYCBP2 is a 3 
non-lysine E3 ligase25, aminolysis activity must be mitigated. Thus, employment of a tempered 4 
form of the E2~Ub conjugate could satisfy the requirements for elevated reactivity to mediate 5 
transthiolation with the mobile upstream cysteine whilst remaining below the threshold for 6 
lysine aminolysis activity. To test if the rotated form of the E2~Ub intermediate engaged by 7 
the RCR had attenuated reactivity we turned to a version of the RCR where Cys4520 is mutated 8 
to alanine. This abolishes competition with native E2-E3 transthiolation allowing assessment 9 
of enhanced rate of Ub discharge to free lysine11. We found that RCR Cys4520Ala did not 10 
enhance lysine discharge activity, supportive of the E2~Ub conformation engaged by 11 
MYCBP2 having attenuated reactivity relative to model, dimeric RING E3 systems (Extended 12 
Data Fig. 5j)7-9. Although the crystallographic Ub rotation could account for the attenuated 13 
E2~Ub reactivity we observe, we cannot formally exclude the former is imparted by crystal 14 
packing and activity attenuation is achieved by an alternative mechanism (Extended Data Fig. 15 
6). 16 
 17 
  18 
 9 
MYCBP2 RING–E2 interface  1 
 2 
It was previously assumed that the RCR RING domain binds E2 and the structure 3 
reveals that a canonical interface is largely adopted albeit with distinct molecular contacts (Fig.  4 
3a, 3c, Extended Data Fig. 7). Consistent with a closed-like E2~Ub conformation, there is no 5 
RING insertion to prevent its formation15,16 (Extended Data Fig. 7h). In fact, the contrary 6 
appears to be the case as the helix-turn-helix motif renders the RCR incompatible with an open 7 
conformation (Extended Data Fig. 8a) Hence, a role for the helix-turn-helix motif might be to 8 
prevent engagement of an open E2~Ub conjugate, which based on our observations would be 9 
catalytically unproductive. 10 
Interactions between the MYCBP2 RING domain and E2 shared with canonical RING-11 
E2 interactions include the E2 loop 2 residue Pro95 engaging the core of the RING (Ile4392, 12 
Phe4394, Val4420, and Pro4438) (Fig. 3a, Extended Data Fig. 9) and alanine mutation of 13 
Ile4392 or F4394 reduces RCR isopeptide formation by ~30 % (Fig. 2c). A difference 14 
associated with the loop 1 interaction is that between E2 Phe62 and the RCR RING (Fig. 3a). 15 
Typically the Phe side chain docks into a shallow hydrophobic pocket within the RING domain 16 
and Phe mutation impairs or even abolishes canonical RING activity7,40. In the case of the RCR 17 
RING, the Phe62 pocket is deeper and highly basic and complementarity toward Phe62 is now 18 
achieved via a cation-pi interaction with RING Arg4419 (Fig. 3a). 19 
A striking feature of the RCR RING is its pronounced loop extension25. The complexed 20 
structure reveals that this serves as an extended docking site for E2 where it complements an 21 
E2 region not previously implicated with RING binding (Fig. 3b). In this context, E2 Arg90 22 
H-bonds to Leu4426 within the RING extension. To probe this interaction, we mutated E2 23 
Arg90 to Ala and made a charge-swapped Arg90Glu mutant. Its importance is supported as 24 
activity drops by 40 % and 70 %, respectively (Fig. 2c). However, E2-RING recognition is 25 
cumulative as even a double Ile4392Ala Leu4426Ala mutant that disrupts both the RING 26 
extension and the canonical interface retained 20 % activity (Fig. 3c).  27 
An anomalous characteristic of the RCR is that despite being an E3 that undergoes 28 
transthiolation, it is not functional with the E2 UBE2L325, which was understood to support E3 29 
transthiolation activity with most, if not all, catalytic cysteine-dependent E3s11. Our structural 30 
insights reveal that incompatibility with UBE2L3 can be primarily ascribed to the presence of 31 
Lys96 (homologous to Ser94 in UBE2D3) which would clash with the MYCBP2 RING 32 
domain (Fig. 3d). However, we could not impart UBE2L3 compatibility by mutation of the 33 
 10 
offending Lys96 to serine suggesting that inactivity might be multifactorial (Extended Data 1 
Fig. 8b). 2 
 3 
Ubiquitin relay is mediated by a helix-coil transition 4 
 5 
Strikingly, our structure reveals that during E2-E3 Ub transfer the disordered mediator 6 
loop transiently adopts an ordered helical conformation (Fig. 4a). This implies that once 7 
MYCBP2 Cys4520 has been thioesterified with Ub, subsequent relay to the downstream 8 
Cys4572 residue would require a distance of at least ~21 Å to be traversed to facilitate 9 
intramolecular transthiolation (Fig. 4a). Analogous intramolecular peptide acyl transfer 10 
reactions have been observed in simple organisms41, where the tertiary structure of the enzyme 11 
brings acyl donor and nucleophilic acceptor in close proximity42. However, in the case of RCR 12 
Ub relay, substantial remodelling of the mediator “loop’s” pre-helical state would be 13 
required25. We tested the side chain properties of selected mediator loop residues for a potential 14 
role in Ub relay using an alanine scan. To deconvolute defects in E2-E3 transthiolation from 15 
Ub relay, which are concerted, we initially assessed Cys4520~Ub thioester formation 16 
independently (Fig. 4b), prior to assessment of Ub relay to a dead-end product (Fig. 4c). With 17 
the exception of the C4520A mutant, which abolishes thioester formation as expected, all 18 
alanine mutants retain WT levels of E2-E3 transthiolation activity (Fig. 4d). Strikingly, Ub 19 
relay was also found to be extremely robust and unperturbed by any of the side chain mutations 20 
(Fig. 4e). Ablation of E2-E3 transthiolation and Ub relay required an amino acid deletion 21 
(ΔA4518) upstream of Cys4520 (Fig. 4a, Extended Data Fig. 8c-d). 22 
The permissive nature of the mediator loop led us to consider backbone perturbation 23 
using a proline scan where mutation would render helix formation less thermodynamically 24 
favourable43. Whereas this largely does not perturb E2-E3 transthiolation (Fig. 4f), all proline 25 
substitutions impair Ub relay (Fig. 4g). The most severe substitutions tend to be at sites 26 
immediately proximal of Cys4520 where Ala4518Pro and Asp4521Pro reduce relay by 80 % 27 
and 70 %, respectively. These observations suggest that whilst helix formation is not necessary 28 
for E2-E3 transthiolation, it is required for efficient Ub relay. As the mediator loop was found 29 
to be fully disordered in the apo structure25, and has elevated B-factors in our transfer complex 30 
(Extended data Fig. 2d, e), we propose Ub relay is facilitated by the mediator loop undergoing 31 
an entropically-driven helix-coil transition. Helix-coil transitions have been studied 32 
extensively in model peptides44,45, but to our knowledge, have not been directly implicated 33 
with catalysis.  34 
 11 
 1 
RCR is central to neurodevelopment and axon protection 2 
 3 
Loss of MYCBP2 E3 ligase activity is likely to be central to the axon protective 4 
phenotype as RING mutants in Drosophila cells stabilize the axon survival factor NMNAT229. 5 
However, it is unclear whether loss of E2-E3 transthiolation, intramolecular Ub relay, and 6 
substrate esterification are linked to the neural phenotypes. We generated homozygous knock-7 
in mice that express an orthologous upstream cysteine to alanine mutant rendering all aspects 8 
of RCR activity defective (Phr1C4629A/C4629A). Expression levels of Phr1 were found to be 9 
consistent across genotypes (Extended Data Fig. 10a), Activity-based proteomics and gel shift 10 
analysis of mouse embryonic fibroblasts (MEFs) also confirmed RCR E3 activity was 11 
abolished in homozygous samples (Fig. 5a, Extended Data Fig. 10b, c). Furthermore, 12 
expression levels of the Phr1 substrate NMNAT2 when transiently expressed in MEFs were 13 
elevated in homozygous samples (Extended Data Fig. 10d). To assess whether loss of RCR 14 
activity specifically is likely to recapitulate perinatal lethality observed with null mice, we 15 
imaged innervation of the diaphragm by the phrenic nerve in embryonic day 18 (E18.5) mice 16 
(Fig. 5b)19,21,22,26. Consistent with previous studies with null mice we found defective 17 
innervation of the diaphragm in Phr1C4629A/C4629A relative to Phr1C4629A/+, as shown by the 18 
marked reduction of secondary branches of the phrenic nerve (Fig. 5b, Extended Data Fig. 19 
10e). Stunting of neurite outgrowth was also observed in primary superior cervical ganglion 20 
(SCG) neurons from E18.5 Phr1C4629A/C4629A mice relative to wild-type and heterozygous 21 
littermates (Fig. 5c, d). 22 
Next, we tested the stunted neurites for axon protection in transection assays. 23 
Remarkably, despite starting from a higher base, absolute degeneration index measurements 24 
are significantly lower at 8 hours post injury indicating neurite protection (P £ 0.0001) (Fig. 25 
5e, f). To normalise for reduced neurite growth and health in Phr1C4629A/C4629A mice relative to 26 
Phr1+/+and Phr1C4629A/+ (resulting in a higher absolute degeneration index at time 0 h), we also 27 
measured change in degeneration index46 (Fig. 5f). In these cultures it is impossible to separate 28 
the effects of the developmental phenotype from axon protection, but the stunted growth of the 29 
Phr1C4629A/C4629A appears more likely to partially mask the protective effect than to contribute 30 
to it. These results indicate that loss of the novel RCR mechanism, followed by substrate 31 
esterification, is responsible for the neurodevelopmental defects and axon protection in adult 32 
mice (Fig. 6). Thus, inhibition of the RCR mechanism in adult animals could be a valuable 33 
 12 
strategy for the treatment of neurodegenerative diseases and neurologic disorders linked to 1 




The discovery that MYCBP2 RCR uses catalytic features hitherto considered the 6 
reserve of canonical RING E3s demonstrates the unappreciated diversity of E3 ligases. Our 7 
study demonstrates that RING domains can stabilize closed E2~Ub conformations to facilitate 8 
Ub transfer to not only lysine, but also cysteine. The extent of E2~Ub activation can be 9 
modulated by the E3 depending on the context of the acceptor site. We anticipate that this 10 
mechanism is adopted more widely by the hundreds of RING E3s for substrate ubiquitination. 11 
Highly templated and sterically unhindered sites may also be ubiquitinated by a similarly 12 
intermediate state of RING-mediated E2~Ub activation, whereas robust stabilization of the 13 
closed, activated state might be reserved for more dynamically and sterically challenging sites. 14 
Indeed, it has been shown that RING E3s can demonstrate attenuated activity as a means of 15 
tuning substrate specificity47. The engineered suicide substrate approach enabled structural 16 
elucidation of a highly transient rate-limiting helical intermediate and granted insights into the 17 
Ub relay process. Our proposal that Ub relay is mediated by a helix-coil transition provides a 18 
framework for how intrinsic disorder might directly facilitate ubiquitin transfer and enzyme 19 
catalysis more generally.  20 
We establish that the mechanistically non-homologous Ub relay and non-lysine 21 
esterification activities demonstrated by MYCBP2 are likely to be central to the axon protective 22 
phenotypes. Our latter inference is based on the observation that MYCBP2 has no lysine 23 
activity and will in fact inhibit intrinsic E2 lysine activity through non-productive E2-E3 24 
transthiolation25. The most likely target of MYCBP2 non-lysine E3 activity is NMNAT227,29, 25 
either through direct or indirect ubiquitination and destabilization. This presents an exciting 26 
therapeutic opportunity for pharmacologically inhibiting Wallerian-like axon degeneration 27 
which has been implicated with a number of neurological conditions such as neuropathies and 28 
neurodegenerative diseases28. Indeed, one protein downstream of MYCBP2 is SARM1, which 29 
is another positive regulator of the Wallerian process48. The discovery of SARM1 having 30 
enzymatic activity has led to it becoming an attractive therapeutic target49,50. The structural and 31 
biochemical insights obtained herein pertaining to MYCBP2 could similarly inform and 32 
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Fig. 1. Stabilization strategy and structure determination of the tetrahedral E2~Ub-2 
MYCBP2 transfer intermediate. a, Native mechanism for Ub transfer to the upstream RCR 3 
C4520 residue by means of transthiolation with E2~Ub. A transient tetrahedral intermediate is 4 
formed prior to intramolecular relay to a downstream cysteine (C4572). b, A chemically 5 
engineered E2~Ub conjugate acts as an activity-based probe (ABP) and chemically traps the 6 
otherwise transient tetrahedral transfer intermediate. ABP design surrogates the final three Ub 7 
residues with an ethyl linker, a triazole (Trz) group, and a cysteine-reactive activated 8 
vinylsulfide (AVS) warhead. c, Domain architecture of the catalytic RCR ligase machinery. d, 9 
The asymmetric unit consists of a single ternary complex. The RCR machinery in surface 10 
representation; RING domain (blue), linker helix (purple), helix-turn-helix (green), TC domain 11 
(orange). The trapped tetrahedral Ub transfer intermediate and Trz moiety are depicted in ball 12 
and stick. The E2~Ub conjugate is in cartoon representation. The E2 is colored mauve and Ub 13 
is gray. e, Closeup view of Ub transfer from E2~Ub to the upstream RCR 4520 residue. Upon 14 






Fig. 2. The RCR engages a closed-like E2~Ub conformation to facilitate exclusive 2 
transthiolation to cysteine within a transient helix. a, E2 superposition of canonical 3 
RNF4:E2~Ub complex (PDB 4AP4) with MYCBP2:E2~Ub complex (TC domain has been 4 
omitted). The RNF4 RING is light blue and its bound E2 and Ub components are wheat and 5 
light pink7, respectively. For the E2~Ub:RCR complex, the tetrahedral crosslink and Trz 6 
moiety are depicted in ball and stick. Inset is depicted the crystallographically observed rotation 7 
of the Ub molecule. This represents an altered closed-like conformation. b, Close up of the 8 
interface between the rotated Ub molecule and the E2. c, To validate the structure we designed 9 
a single turnover E2-E3 isopeptide assay based on a C4520K E3 mutant (Extended Data Fig. 10 
4). Quantification of E2-E3 isopeptide assays (n = 3 independent experiments performed with 11 
identical purified proteins). Ub Gln40 is proximal to the helix-turn-helix motif but does not 12 
form a discernible interaction. Consistent with this, the Gln40Ala mutation has no effect. For 13 
representative gel data see Extended Data Fig. 3 c, d. d, Close-up view of the engineered, 14 
tetrahedral E2~Ub-RCR transthiolation intermediate. The oxyanion, (a proton in our 15 
engineered intermediate), has been schematically added to the structure. 16 
 17 
  18 
 20 
 1 
Fig. 3. MYCBP2 RING-E2 interface involves a novel RING extension and specificity 2 
determinants. a, Canonical RING-E2 interface involving E2 Pro95 engagement with the core 3 
of the RING domain. b, The canonical interface is supplemented by interactions with the 4 
characteristic MYCBP2 RING extension which contacts an E2 region not previously 5 
implicated with E2 recognition. This is exemplified by the E2 R90 interaction with MYCBP2 6 
L4426. c, Native single turnover E2~Ub discharge assay. Here, E2 is loaded with Ub and 7 
reloading is prevented by addition of E1 inhibitor. Discharge of Ub from E2~Ub mediated by 8 
addition of MYCBP2 RCR and threonine (50 mM) is monitored. Image is representative 9 
replicate with quantification below (n = 3 independent experiments performed with identical 10 
purified proteins). d, E2 sequence alignment highlights difference between MYCBP2 11 
compatible E2s and UBE2L3. Superposition of UBE2L3 (pink; PDB 4Q5E) with UBE2D3 12 
(mauve) from the RCR E2~Ub complex. In the superposition UBE2L3 Ser91 cannot interact 13 
with the RCR RING extension and UBE2L3 Lys96 is sterically incompatible when introduced 14 











Fig. 4. Alanine and proline scanning of the mediator loop. a, Structural rearrangement of 2 
the evolutionarily-conserved mediator loop would be required to relay Ub between C4520 and 3 
C4572. b, Mutation of the downstream cysteine to alanine allows direct assessment of native 4 
E2-E3 transthiolation activity. c, Mutation of the downstream cysteine to serine restricts RCR 5 
activity to the formation of a dead-end ester-linked Ub adduct. For mutants that had negligible 6 
effect on E2-E3 transthiolation, reductions in activity can be directly ascribed to Ub relay. d, 7 
Assessment of alanine scan on E2-E3 transthiolation. B-ME corresponds to 2-mercaptoethanol. 8 
e, Assessment of alanine scan on Ub relay. f, Assessment of proline scan on E2-E3 9 
transthiolation. g, Assessment of proline scan on Ub relay. All SDS-PAGE gel images are 10 
representative replicates with quantification below (n = 3 independent experiments performed 11 





Fig. 5. Neurodevelopmental defects and delayed axotomy-induced axon degeneration in 2 
Phr1C4629A/C4629A SCG neurons. a, Transthiolation activity-based proteomics of E1s and 3 
RCR/RBR/HECT E3s in extracted proteomes from MEFs. Signals were normalised to UBA1 4 
(n=2 biological replicates). ABP was withheld in the control experiment allowing assessment 5 
of non-specific resin binding. b, βIII-tubulin (Tuj1) immunostaining of the right phrenic nerve 6 
terminal branches reveals defective diaphragm innervation in E18.5 Phr1C4629A/C4629A embryos. 7 
Boxed regions are magnified (right). Acetylcholine receptor (AChR) clusters are labeled by 8 
counter-staining with bungarotoxin-TRITC. Representative images from 4 HOM and 9 HET 9 
animals. c, Representative images of neurite outgrowth at DIV7 in Phr1C4629A/+ and 10 
Phr1C4629A/C4629A SCG explant cultures. d, Quantification of neurite outgrowth at DIV3-5-7; n 11 
numbers per genotype are indicated in the figure (mean ±SEM; mixed-effects model followed 12 
by Tukey post-hoc test).  e, Representative phase contrast images of neurites from Phr1+/+, 13 
Phr1C4629A/+ and Phr1C4629A/C4629A SCG explant cultures at the indicated time points after 14 
axotomy. f, Quantification of the degeneration index in experiments described in (e) from 3 15 
fields per sample; n numbers per genotype are indicated in the figure. Change in degeneration 16 
index is also shown (mean ±SEM; two-way RM ANOVA followed by Tukey post-hoc test). 17 
Asterisks indicate: * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001, or NS P > 0.05). 18 
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 1 
Fig 6. Model for the central role of MYCBP2 RING-Cys-Relay activity in neural 2 
development and axon maintenance. The E2~Ub conjugate samples multiple conformations 3 
in solution and the mediator loop is unstructured. The RCR machinery in MYCBP2 engages 4 
an activated conformation of the E2~Ub conjugate and the mediator loop adopts a transient a-5 
helix whilst undergoing transthiolation. The RING domain serves as an E2 docking site and 6 
the TC (tandem cysteine) domain contains both upstream and downstream catalytic cysteines. 7 
Upon E2 dissociation, Ub relay to the downstream cysteine is mediated by an entropically 8 
driven helix-coil transition. The downstream site is endowed with esterification activity rather 9 
than conventional aminolysis activity. Modification of a threonine (Thr) residue in a 10 
polypeptide substrate occurs in vitro but this remains to be confirmed in vivo. Substrate 11 
modification is required for normal neural development and programmed axon degeneration 12 
in response to injury.   13 
 24 
Online Methods  1 
 2 
General materials 3 
 4 
All DNA constructs generated for this study were verified by DNA sequencing and 5 
are available on request through the Medical Research Council Protein Phosphorylation and 6 
Ubiquitylation Unit, University of Dundee, reagents website 7 
(https://mrcppureagents.dundee.ac.uk/). Chemical probes and mouse line described in this 8 
study are available upon request under a material transfer agreement. 9 
 10 
Purification and crystallisation of a covalent RCR-UBE2D3-Ub complex. 11 
 12 
MYCBP2 residues 4385-4640 were expressed as a GST fusion. Residue numbering for 13 
the Uniprot entry for human MYCBP2 (075592) differs as its reannotation has added 38 14 
residues to the protein N-terminus. Following cleavage of the GST tag, MYCBP2 was 15 
exchanged by size exclusion chromatography (SEC, Superdex-75) into 20 mM Na2HPO4 pH 16 
7.5, 150 mM NaCl, 1 mM TCEP. Ubiquitin (residues 1-73) activity based probe (ABP), 17 
containing a thioacrylamide warhead and a UBE2D3 (C21S, S22R, C107S, C111S) 18 
recognition element, was prepared as previously described30. ABP (200 µM) and MYCBP2 19 
(50 µM) were exchanged into 20 mM Na2HPO4 pH 7.5, 150 mM NaCl and incubated for 4 hr 20 
at 30 °C to generate a ternary MYCBP2-UBE2D3-Ub complex. Probe-labelled MYCBP2 21 
was exchanged into 20 mM HEPES pH 7.5, 150 mM NaCl, 1 mM TCEP by SEC. Fractions 22 
containing probe-labelled MYCBP2 were pooled and concentrated to 5 mg/mL for 23 
crystallisation. Crystals were obtained by vapour-diffusion in 0.85 M sodium citrate, 100 24 
mM sodium chloride, 100 mM Tris-HCl pH 8.0. Single crystals were soaked in mother 25 
liquor supplemented with 35% glycerol and vitriolized in liquid nitrogen. Data were 26 
collected at the European Synchrotron Radiation Facility at Beamline ID29 (λ = 1.2737 Å). 27 
A total of 360° of data were collected with an oscillation range of Ω = 0.1°. Diffraction data 28 
were integrated using XDS51 and scaled using Aimless52 (version 0.7.3) from the CCCP4 29 
package (version 7.0). Phases were obtained by molecular replacement in Phaser53 (version 30 
2.8.2) using apo-MYCBP2 (PDB 5O6C), UBE2D3 (5EGG), and Ub (PDB 1UBQ) as the 31 
search models. Manual model building was carried out with Coot54 (version 0.8) and 32 
refinement with REFMAC555 (version 5.8.0238). Ramachandran statistics were, favoured: 33 
92.04%, allowed: 6.45%, outliers: 1.51%. Clear electron density for the engineered 34 
 25 
bisthioether linkage between UBE2D3 Cys85 and MYCBP2 Cys4520 was visible. To model 1 
the linkage a ligand was parameterised using the electronic Ligand Builder and Optimization 2 
Workbench (eLBOW) module of the PHENIX suite56 (version 1.14). The ligand excluded 3 
the ethyl group between Leu73 and the triazole (Trz) as Leu73 was disordered in the 4 
structure. The sulphur atoms of Cys85 and Cys4520 were included as part of the ligand. 5 
Simulated annealing 2|mFo|-|dFc| composite omit maps were generated using the module 6 
within the PHENIX suite57(version 1.14).  7 
 8 
Single-turnover E2 discharge by in-gel fluorescence 9 
 10 
Cy3B-labeled ubiquitin was prepared as described previously25. Assays were carried 11 
out in Assay Buffer: 20 mM sodium phosphate pH 7.5, 150 mM NaCl, 5 mM MgCl2, 5 mM 12 
ATP. E2 (10 µM) was charged by E1 (~ 600 nM) with Cy3B-labelled ubiquitin (12.5 µM) 13 
at 37 °C for 30 min then cooled at 23 °C for 3 min. E2 recharging was then blocked by the 14 
addition of an E1 inhibitor (MLN4924 derivative, compound 158, (25 µM)), and further 15 
incubated for 10 min. The mixture was then mixed with an equal volume of cleaved 16 
MYCBP2 (residues 4378-4640) (5 µM) and threonine (100 mM) and incubated at 23 °C for 17 
the specified time. For MYCBP2 C4520A and RNF4 (residues 1-194)7 the final E3 18 
concentrations were 5  µM and 0.5 µM, respectively, and lysine concentrations were 0-200 19 
mM. Although efficient lysine discharge was observed with the RCR C4520K mutant, the 20 
structural context of this acceptor lysine templates the reaction which can increase the reaction 21 
rate by multiple orders of magnitude, thereby reconciling the lack of activity towards free 22 
lysine which would be diffusion-limited39,59. For MYCBP2 C4520K mutants, threonine was 23 
omitted from the buffer. The reactions were terminated by the addition of 4X LDS loading 24 
buffer Thermo Fisher Scientific) with or without 2-mercaptoethanol. SDS-PAGE gels were 25 
scanned with a ChemiDoc MP Gel Imaging System with Image Lab software version 6.0.1 26 
(Bio-Rad Laboratories) and Cy3B fluorescence intensity was quantified using ImageJ 27 
version 1.51. Single-turnover Ub-discharge kinetic data were fitted with a one-phase 28 
exponential association curve using Prism 7 (Graphpad Software, Inc). 29 
  30 
Multiple turnover E2-discharge panel. 31 
 32 
 26 
Indicated E2s (1 µM) were incubated in Assay Buffer with MYCBP2 C4520K (5 µM), 1 
Ub (20 µM), E1 (250 nM), 5 mM ATP.  2 
 3 
Mediator loop alanine/proline scanning 4 
 5 
Mediator loop mutations were introduced into the C4572A or C4572S backgrounds of 6 
MYCBP2. E2 charging with Cy3B ubiquitin was carried out as described for single-turnover 7 
E2 discharge by in-gel fluorescence, except E1 was not inhibited. The reactions were 8 
terminated by the addition of 4X LDS loading buffer (Thermo Fisher Scientific) (either non-9 
reducing or reducing). For MYCBP2 C4572S ester bond cleavage, 0.14 N NaOH was added 10 
and samples were further incubated at 23 °C for 20 min. 11 
 12 
Generation of Phr1C4629A/C4629A knock-in mice 13 
 14 
            A C4629A knock-in mutation was created in the MYCBP2 gene (NCBI transcript 15 
NM_207215.2) encoding mouse MYCBP2/Phr1 using CRISPR/Cas9-mediated gene-editing 16 
technology (performed by Taconic Biosciences GmbH, Köln, Germany), C57BL/6NTac-17 
Mycbp2em5686(C4626A)Tac. In summary, a guide RNA corresponding to the sequence 18 
TGAGGCTCGCTGTGATGCTG was used to target exon 83 of the Phr1 gene on chromosome 19 
14. This replaced the native cysteine codon (TGT) at position 4629 for an alanine codon. The 20 
guide also introduced a single silent mutation immediately upstream thereby introducing an 21 
XhoI restriction site for analytical purposes (TGAGGCTCGAGCAGATGCTG). This reduces 22 
the codon usage probability for amino acid R4628 from 9.4 % to 6.6 %. Potential F0 founder 23 
animals were screened by PCR using extracted biopsies and XhoI positive products were 24 
sequenced. Prediction of potential off target sites, revealed that the two closest genes had 3 25 
mismatches. These, together with the next 6 closest matches and two ubiquitin system targets 26 
with 4 mismatches (USP37 and WWP2), were PCR screened revealing none were disrupted. 27 
Founder mice were backcrossed, and transmission of the MYCBP2 C4629A was confirmed by 28 
direct sequencing of PCR products. Frozen sperm from G1 MYCBP2 C4629A heterozygous 29 
mice was received by the University of Dundee animal facility and used for in 30 
vitro fertilization of C57BL/6J oocytes, collected from superovulated females. The same 10 31 
potential off-target sites were screened with various primer pairs, and were confirmed to be 32 
non-mutated by sequencing. Genotyping of the knock-in allele was routinely performed by 33 
 27 
PCR using the forward 5’-CACACTTGGAAACCCATGC-3’ and reverse 5’-1 
ATGACTAGCTTCATGTGTACCCC-3’ followed by digestion of the PCR product with 2 
XhoI. For a wild type allele, this results in a band of 590 bp while a targeted allele gives a band 3 
of 421 bp.  4 
Mice were backcrossed on a C57BL/6J (Charles River UK) background for two 5 
generations and provided with free access to food (R&M3 pelleted irradiated diet) and water. 6 
Animals were kept in individually ventilated cages at 21 °C, 45-65 % relative humidity and a 7 
12 h/12 h light/dark cycle under specific-pathogen–free conditions in accordance with UK and 8 
European Union regulations. Experiments on mice were approved by the University of Dundee 9 
ethical review board under a UK Home Office project license. 10 
 11 
CRISPR/Cas9-mediated MYCBP2 knock-out of SH-SY5Y cells 12 
 13 
The MYCBP2 KO SH-SY5Y line was generated using a lentiviral vector, 14 
lentiCRISPRv2 (Addgene plasmid # 52961), encoding a single guide RNA scaffold targeting 15 
the first exon of MYCBP2 (spacer sequence: GCCTCCGGTAGCGGTCGGCCA). After 16 
transduction, cells were initially selected with puromycin, and later subjected to limiting 17 
dilution to obtain a homogenous MYCBP2 KO cell population. 18 
 19 
Primary neuronal cultures 20 
 21 
SCG explants were dissected from Phr1+/+, Phr1C4629A/+ and Phr1C4629A/C4629A littermate 22 
E18.5 mouse embryos. Explants were cultured in 35 mm tissue culture dishes pre-coated with 23 
poly-L-lysine (20 µg/ml for 1 hr; Sigma) and laminin (20 µg/ml for 1 hr; Sigma) in Dulbecco's 24 
Modified Eagle's Medium (DMEM, Gibco) with 1 % penicillin/streptomycin, 50 ng/ml 2.5S 25 
NGF (Invitrogen) and 2 % B27 (Gibco). 4 µM aphidicolin (Merck) was used to reduce 26 
proliferation and viability of small numbers of non-neuronal cells. Culture media was 27 
replenished every 3 days. Neurites were allowed to extend for 7 days before performing the 28 
experiments. 29 
 30 
Acquisition of phase contrast images, neurite outgrowth and axon degeneration assays 31 
 32 
Phase contrast images were acquired on a DMi8 upright fluorescence microscope 33 
controlled with LAS X software (Leica Microsystems) coupled to a monochrome digital 34 
 28 
camera (Hammamatsu C4742-95). The objectives used were NPLAN 5X/0.12 for neurite 1 
outgrowth assays and HCXPL 20X/0.40 CORR for axon degeneration assays. SCG explants 2 
and their extending neurites were captured at low magnification at DIV7. Radial outgrowth 3 
was determined by taking the average of two measurements of representative neurite outgrowth 4 
for each explant. Measurements were made from overlapping images of the total neurite 5 
outgrowth. Axon degeneration assays were performed in the same SCG cultures used for the 6 
assessment of neurite outgrowth. Neurites were cut with a scalpel and axon degeneration 7 
index60, was determined using an ImageJ plugin (http://rsb.info.nih.gov/ij/download.html) 8 
which calculates the ratio of fragmented axon area over total axon area after binarization of the 9 
pictures and subtraction of the background.  10 
Whole-mount immunostaining of diaphragms and branch number quantification 11 
E18.5 mouse embryos were fixed by immersion in 4% (w/v) paraformaldehyde for 24 12 
hours at 4°C. Diaphragms were dissected and washed in phosphate-buffered saline (PBS) 13 
before incubation with 10 µg/ml tetramethylrhodamine (TRITC)-conjugated α-bungarotoxin 14 
(Thermo Fisher Scientific) for 20 mins at room temperature. Samples were then 15 
permeabilized/blocked in PTX (PBS, 0.5% Triton-X100) with 4% BSA (Sigma) for 2 hours at 16 
room temperature and incubated overnight at 4 °C with an anti-βIII-tubulin (Tuj1) antibody 17 
(Sigma, T2200) in blocking solution (1:500 dilution). Following multiple washes in PTX, 18 
diaphragms were incubated with an AlexaFluor488-conjugated anti-rabbit antibody (Thermo 19 
Fisher Scientific A11008) (1:200 dilution) in blocking solution for 5 hours at room temperature 20 
and again extensively washed in PTX. Diaphragms were finally mounted in Vectashield 21 
(Vector Laboratories) and images were acquired on a DMi8 upright fluorescence microscope 22 
(Leica Microsystems) coupled to a monochrome digital camera (Hammamatsu C4742-95), 23 
using a NPLAN 5X/0.12 objective. For quantification of secondary branch number, we traced 24 
a parallel line 100 µm below the primary branches, keeping the distance constant across 25 
samples. The number of secondary branches that crossed the line were counted. 26 
Mouse Embryonic Fibroblast (MEF) isolation 27 
 28 
E12.5 embryos were decapitated, minced, incubated in trypsin-EDTA (Gibco), and 29 
pelleted by centrifugation. Cells were resuspended in high glucose DMEM (Gibco) 30 
supplemented with 10 % fetal bovine serum (Sigma), 1 mM sodium pyruvate (Gibco), non-31 
essential amino acids (Gibco), 100 U/mL penicillin-streptomycin (Gibco), 2 mM L-glutamine 32 
 29 
(Gibco). Cells were then plated in 100 mm dishes, and maintained at 37 °C in 5% CO2. For 1 
proteomics experiments, MEFs were rinsed, scraped manually in Dulbecco's Phosphate-2 
Buffered Saline (DPBS, Gibco), and pelleted by centrifugation. Cells were resuspended in 3 
DPBS and pelleted by centrifugation. Cell pellets were snap frozen in liquid nitrogen and stored 4 
at -20°C. 5 
 6 
NMNAT2-HA expression in mouse embryonic fibroblasts 7 
 8 
Mouse embryonic fibroblasts were plated in a 6-well plate at a density of 2 x 106 cells 9 
per well. The following day, 1 µg of C-terminal HA-tagged human NMNAT2-coding plasmid, 10 
or empty vector, were transiently transfected using Lipofectamine 2000 (Invitrogen) at a 11 
Lipofectamine:DNA ratio of 5:1 in Opti-MEM (Gibco). After 24 h, cells were harvested, lysed, 12 
and both soluble protein and insoluble proteins were subjected to Western blot analysis. The 13 
insoluble fraction was dissolved in 2 % (w/v) SDS prior to addition of 4X LDS sample buffer 14 
(Thermo Fisher Scientific).  15 
 16 
MYCBP2 probe-labelling for immunoblot analysis 17 
 18 
An ABP, containing maltose binding protein (MBP) fused to the N-terminus of a 19 
UBE2D3 (C21S, C107S, C111S) and Ub residues 1-73, was prepared as previously 20 
described30. To assess MYCBP2 probe labelling, MEF or SH-SY5Y lysates (100 µg) were 21 
incubated in lysis buffer (50 mM Tris-HCl pH 7.5, 1 mM EGTA, 1 mM EDTA, 10 mM 22 
glycerophosphate, 50 mM sodium fluoride, 5 mM sodium pyrophosphate, 1 mM sodium 23 
vanadate, 0.27 M sucrose, 1% NP-40, 0.2 mM PMSF, 1 mM benzamidine, (complete EDTA-24 
free protease inhibitor cocktail (Roche)) with 12 µM MBP-ABP for 4 h at 30 °C. Reactions 25 
were terminated by the addition of 4X LDS loading buffer (Thermo Fisher Scientific) 26 
containing 2-mercaptoethanol prior to immunoblot analysis.  27 
 28 
Immunoblot analysis 29 
 30 
Harvested cells were resuspended in lysis buffer with complete EDTA-free protease 31 
inhibitor cocktail (Roche). Protein concentration in clarified lysates was assessed using the 32 
Bradford method. Samples were prepared in 4xLDS sample buffer (Thermo Fisher Scientific) 33 
containing 2-mercaptoethanol. Electrophoresis was performed at 150 V in a NuPAGE 3-8% 34 
 30 
Tris-Acetate gel (Invitrogen) when blotting for MYCBP2 or a NuPAGE 4-12% Bis-Tris gel 1 
(Invitrogen) for NMNAT2-HA. Following electrophoresis proteins were transferred to PVDF 2 
membrane. Membranes were blocked in TBS-T (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 3 
0.05% Tween-20) containing 5% (w/v) non-fat dried skimmed milk powder for 1 h before 4 
incubation with commercially available primary antibody (MYCBP2 Abcam Ab86078 5 
1:10,000 dilution, HA tag 3F10 Sigma 27573500 1:2500 dilution, Vinculin Abcam Ab129002 6 
1:2500 dilution, Tubulin ProteinTech 66031 1:10,000 dilution) or a previously described 7 
antibody raised against the RCR domain (anti-MYCBP2 SA357 aa4378-464025 1:1200 8 
dilution). After washing in TBST-T, membranes were incubated for 45 min in secondary HRP-9 
coupled antibody (anti-Rabbit Cell Signaling Technology 7074S 1:5000 dilution, anti-Rat Cell 10 
Signaling Technology 7077S 1:5000 dilution, anti-Sheep Invitrogen 31480 1:5000, or anti-11 
Mouse Cell Signaling Technology 7076S, 1:5000 dilution). Membranes were then washed 12 
before adding the chemiluminescent substrate (ECL Prime Sigma, for ABP-labelling 13 
experiment and NMNAT2-HA; ECL Thermo Fisher Scientific, for MYCBP2 and Tubulin), 14 
and exposing to radiographic film. 15 
 16 
Activity-based proteomics 17 
 18 
MEFs from WT and homozygote genotypes were rinsed and collected with ice-cold 19 
PBS, and extracted with ice-cold lysis buffer 2 (50 mM Tris-HCl pH 7.5, 10 mM sodium 2-20 
glycerophosphate, 50 mM sodium fluoride, 5.0 mM sodium pyrophosphate, 1.0 mM sodium 21 
orthovanadate, 0.27 M sucrose, 50 mM NaCl, 0.2 mM (PMSF), 1.0 mM benzamidine, 10 μM 22 
TCEP, 1% NP-40) on ice for 20 min. Protein concentration in clarified lysates was determined 23 
by Bradford assay and concentrations normalised across genotypes. Biotin-labelled E3 24 
activity-based probe with a UBE2D3 recognition element and Ub residues 1-7325 was added to 25 
lysates at 10 μM and incubated at 30°C for 4 hr. Biotin enrichment was then carried out against 26 
streptavidin resin followed by on-resin tryptic digestion and LC-MS/MS analysis25. Data were 27 
processed using LFQ quantification with MaxQuant (http://www.maxquant.org). To facilitate 28 
graphical depiction, the vast dynamic range of LFQ intensities were normalised to the mean 29 
UBA1 signal in ABP-treated wild-type MEFs. UBA1 is the predominant ubiquitin E1 and 30 




Data availability 1 
 2 
Protein Data Bank coordinates and structure factors for RCR-E2-Ub have been 3 
deposited with accession code 6T7F. All DNA constructs were verified by DNA sequencing 4 
and are available through the Medical Research Council Protein Phosphorylation and 5 
Ubiquitylation Unit, University of Dundee, reagents website 6 
(https://mrcppureagents.dundee.ac.uk/). The data that supports these findings, including raw 7 
mass spectrometry and microscopy data, are available from the corresponding author upon 8 
request s.s.virdee@dundee.ac.uk.   9 
 32 
 1 
Extended Data Fig. 1. Structure determination and representative views of the E2~Ub-2 
MYCBP2 transfer intermediate. a, A crosslinked transfer complex was prepared by 3 
incubating ABP (200 µM) and E3 (MYCBP2 RCR) (50 µM) for 4 h at 30 °C. Complex 4 
formation was assessed by SDS-PAGE (left). The stabilized transfer complex was purified by 5 
size-exclusion chromatography (right). b, Domain architecture of MYCBP2 including the 6 
catalytic RCR machinery. c, The RCR machinery is in stick representation; RING domain 7 
(blue), linker helix (purple), helix-turn-helix (green), TC domain (orange), mediator loop 8 
(brown), E2 (mauve) and Ub (gray). The mesh represents a simulated annealing composite 9 
omit 2|mFo|-|dFc| electron density map contoured at 1.0 σ. d, As above except the mesh 10 
represents the experimental 2|Fo|−|Fc| electron density map contoured at 1.0 σ. e, Close-up 11 
view of the three-way crosslink between E2 C85, RCR C4520 and the Ub carboxy terminus. 12 
 33 
The mesh represents a simulated annealing composite omit 2|mFo|-|dFc| electron density map 1 
contoured at 1.0 σ carved around the mediator loop G4515 – D4529, E2 residues C85, and the 2 
crosslink. f, As e except the mesh represents the experimental 2|Fo|−|Fc| electron density map 3 
contoured at 1.0 σ. g, Close-up view of the Ub-esterification site, in the apo-structure the 4 
esterification site is occupied by a Thr residue due to crystal packing. The mesh represents a 5 
simulated annealing composite omit 2|mFo|-|dFc| electron density map contoured at 1.0 σ 6 
carved around E4534, F4570 – F4573, H4583, F4586 and an ordered water molecule. h, As g 7 




Extended Data Fig. 2. Superposition of apo-MYCBP2 (PDB 5O6C), E2~Ub bound-12 
MYCBP2 and protein crystal stability. a, Apo-MYCBP2 residues Asn4379-His4638 were 13 
aligned with bound-MYCBP2 residues Asp4387-Asn4636. The RCR, E2 and Ub are in cartoon 14 
representation: Coloring (apo-MYCBP2/bound-MYCBP2) zinc ions (light gray/gray), RING 15 
domain (light blue/blue), linker helix (pink/purple), helix-turn-helix (light green/green) and 16 
tandem cysteine domain (yellow/orange). In the apo structure, 8 residues from the mediator 17 
loop are disordered and are represented by a black dashed line. The E2 is colored mauve and 18 
Ub is gray. MYCBP2 Residues Ala4518, Gly4527, Cys4520 and Cys4572 are in ball and stick 19 
representation. In the bound-MYCBP2 structure E2 residue C85 and the engineered crosslinker 20 
are in ball and stick representation. b, Closeup of TC domains, in the E2~Ub bound structure 21 
the eight mediator loop residues, that were disordered in the apo structure, adopt a helical 22 
conformation in the E2~Ub:RCR transfer complex. c, Closeup of RING domains, in the E2~Ub 23 
bound structure the RING domain has twisted towards the linker-helix this results in a 3.0 and 24 
4.1 Å shift of Zn2+ 1 and Zn2+ 2, respectively. d, Representative view of the E2~Ub-MYCBP2 25 
transfer intermediate. e, Representative view of the E2~Ub-MYCBP2 transfer intermediate 26 
colored by B-factors (blue thin-cartoon lowest B-factors to red thick-cartoon highest B-factors) 27 
indicates that ubiquitin and the mediator loop are the most disordered components of the 28 
complex. f, SDS-PAGE gel of purified ABP-MYCBP2 complex and ABP-MYCBP2 complex 29 
recovered from a crystal drop containing the productive conditions (0.85 M sodium citrate, 100 30 
mM sodium chloride, 100 mM Tris-HCl pH 8.0). The ABP-labelled transfer complex is stable 31 




Extended Data Fig. 3. Data collection and refinement statistics. Crystallographic data were 2 





Extended Data Fig. 4. Mutational analysis of E2-E3 Ub transfer was determined by 2 
single-turnover isopeptide formation in the context of an RCR C4520K mutant. To 3 
decouple E2-E3 Ub transfer (what our structure is reflective of) from subsequent relay and 4 
substrate esterification, we devised a robust assay that results in transfer of Ub from E2 to a 5 
dead-end product. To achieve this, we mutated the upstream Cys4520 residue to a lysine 6 
(Cys4520Lys). We found Ub was transferred to the lysine forming a stable isopeptide adduct. 7 
a, Activity was efficient and only E2’s previously shown to support MYCBP2 E3 activity 8 
supported isopeptide bond formation25. Experiment was repeated twice with similar results.  b, 9 
A subset of hallmark interactions involved in closed E2~Ub stabilization are maintained 10 
(coloring as Fig. 2a). c, Representative replicate from single-turnover E2~Ub isopeptide assay 11 
used for quantification presented in Fig. 2c (also see methods). d, The majority of mutants were 12 
also tested with wild type MYCBP2 in multiple turnover threonine-discharge assays (Extended 13 
Data Fig. 5), which yielded similar activity profiles. However, one exception was with E2 14 
 36 
mutation D117A. Whereas D117A was fully active with MYCBP2 WT, it was completely 1 
inactive in C4520K isopeptide formation. This is reflective of this residue having a lysine-2 
specific role that is redundant with native MYCBP2 E2-E3 transthiolation. e-h, Kinetic 3 
analysis for E2 active site residues (n = 3 independent experiments performed with identical 4 
purified proteins). Blue squares and black circles correspond to experiments where E3 was 5 
added or withheld, respectively. E2 reloading was blocked by addition of E1 inhibitor and 6 
depletion of the E2~Ub species was quantified. i, Observed rates of single-turnover Ub 7 
discharge (kobs) from experiments e-h. Observed rate constants were obtained from the one-8 
phase exponential association equation using the routine within Graphpad Prism. Assays were 9 
carried out in triplicate using identical purified proteins. The 95 % confidence intervals for kobs 10 
are presented. ND* indicates that rates of Ub discharge in the presence of E3 were 11 
indistinguishable from background E2~Ub hydrolysis. Observed rates for native transthiolation 12 
activity determined from experiments presented in Extended Data Fig. 5 are also tabulated. 13 
 14 
Extended Data Fig. 5. Mutational assessment of native MYCBP2 E2-E3 transthiolation 15 
activity and demonstration of attenuated E2~Ub reactivity. a, Proposed intramolecular role 16 
for Ub I36 in maintaining a closed-like E2~Ub conformation. The interaction between Ub I36 17 
and L71 is maintained in the “closed-like” E2~Ub conformation. Superposition of the RCR 18 
 37 
E2~Ub and RNF4 E2~Ub (PDB 4AP4) complexes. The gap between Ub I36 and L71 has 1 
decreased by 0.7 Å in the RCR complex. The RCR, E2 and Ub are in cartoon representation 2 
with select residues in ball and stick representation: Ub I36, L71, R72 and the engineered linker 3 
(gray), E2 C85 (mauve), RCR K4441 (blue) and C4520 (orange). The RNF4 E2~Ub complex 4 
is in cartoon representation with select residues in stick representation: Ub I36, L71, R72 5 
(pink), R181 (purple). b, For the selected mutants, MYCBP2 activity was assessed using single 6 
turnover E2~Ub discharge assays mediated by the presence of wild type MYCBP2 and 7 
threonine (50 mM). c, Single turnover E2~Ub discharge assay mediated by the presence of 8 
wild type MYCBP2 and threonine (50 mM) for E2 Asn114Ala and Asn114Gln mutants. 9 
Experiment repeated twice with similar results. d, Quantification for selected mutants, (n = 3-10 
4 independent experiments performed with identical purified proteins). e-i native single-11 
turnover WT MYCBP2 and threonine dependent E2~Ub discharge assay. Observed rate 12 
constants tabulated in Extended Data Fig. 4 were obtained from the one-phase exponential 13 
association equation using the routine within Graphpad Prism. Blue squares and black circles 14 
correspond to experiments where E3 was added or withheld, respectively. (n = 3 independent 15 
experiments performed with identical purified proteins) j, Quantification of lysine discharge 16 
assay in the presence of a transthiolation-defective RCR A4520 mutant or the canonical RING 17 
E3 RNF4 (n = 3 independent experiments performed with identical purified proteins). 18 
Although efficient lysine discharge was observed with the RCR C4520K mutant, the structural 19 
context of this acceptor lysine templates the reaction which can increase the reaction rate by 20 
multiple orders of magnitude, thereby reconciling the lack of activity towards free lysine which 21 
would be diffusion-limited39,59. 22 
 23 
 24 
Extended Data Fig. 6. Consideration of crystal packing effects on adoption of the closed 25 
like E2~Ub conformation and assessment of their significance in solution. a, Interface 26 
between Ub (gray), E2 (mauve) RCR (TC domain, orange; linker helix, purple; helix-turn-27 
helix, green; RING, blue) and two symmetry-related RCR molecules (cyan and light-blue). 28 
The side chain of Ub E18 and the first 7 residues of the RCR construct are disordered. b, 29 
Closeup of the interface between Ub, E2 and symmetry related E3. Ub K48 and R54 are in 30 
close proximity to symmetry related MYCBP2 H4599. c, Superposition of the RCR E2~Ub 31 
and RNF4 E2~Ub (PDB 4AP4) complexes highlighting the position of Ub Lys48. The altered 32 
Ub packing in the RCR complex (E2, mauve: Ub, gray) results in Ub Lys48 shifting away from 33 
E2 D42, relative to the RNF4 complex (E2 wheat; Ub, pink). d, Single-turnover E2~Ub 34 
discharge and single-turnover isopeptide formation for the indicated Ub variants. The Ub 35 
 38 
E18R, A46D, R54E, and N60A mutants were discharged similarly to WT Ub, suggesting that 1 
the interface with a second copy of MYCBP2 does not exist in solution or is not required for 2 
activity. The Ub K48A and K48E mutants reduced activity, which would not be expected if 3 
the interaction with H4599 residue within the symmetry related MYCBP2 contributed to 4 
prevention of a canonical closed-conformation in solution. As K48 is proximal to the E2 it 5 
seems more likely that it intrinsically contributes to closed and closed-like activation. e, 6 
Quantification of single-turnover E2~Ub discharge (n=5 independent experiments performed 7 
with identical purified proteins) and single-turnover isopeptide formation (n=3 independent 8 
experiments performed with identical purified proteins). 9 
 10 
Extended Data Fig. 7. Representative electron density centered on key E2~Ub-RING 11 
interfaces and comparison with E2~Ub-RING1 interfaces. a, The E2-Ub interface is 12 
centred on E2 L104, Ub L8, I44, H68, and V70. E2 (mauve) and Ub (gray) are shown as sticks, 13 
the RCR RING domain (blue) is shown as a cartoon. For clarity RCR regions C-terminal of 14 
 39 
the RING are not shown. The mesh represents a simulated annealing composite omit 2|mFo|-1 
|dFc| electron density map contoured at 1.0 σ. b, As a except the mesh represents the 2 
experimental 2|Fo|−|Fc| electron density map contoured at 1.0 σ. c, View of the RING-E2 3 
interface, RCR RING (blue), E2 (mauve) and Ub (gray) are shown as sticks. The RCR 4 
equivalent to the ‘linchpin’ residue (K4441) and the functionally important RING extension 5 
residue (L4426) are labelled. The mesh represents a simulated annealing composite omit 6 
2|mFo|-|dFc| electron density map contoured at 1.0 σ. d, As c except the mesh represents the 7 
experimental 2|Fo|−|Fc| electron density map contoured at 1.0 σ. e, View of the RING-E2 8 
interface focused on RCR residues L4392, F4394 and the interaction between E2 S94 and 9 
RING P4438. The mesh represents a simulated annealing composite omit 2|mFo|-|dFc| electron 10 
density map contoured at 1.0 σ. f, As e except the mesh represents the experimental 2|Fo|−|Fc| 11 
electron density map contoured at 1.0 σ. g, Superposition of MYCBP2 E2~Ub and HOIP 12 
E2~Ub complexes (PDB 5EDV) highlighting the shift in E2 binding site for HOIP RING1 13 
(E2s were superposed). MYCBP2 complex RING (blue), E2 (mauve), zinc ions (gray); HOIP 14 
complex RING1 (cyan), E2 (wheat), zinc (light gray). h, Superposition of MYCBP2 E2~Ub 15 
and HHARI E2~Ub complexes (PDB 5UDH) highlighting a loop insertion in HHARI RING1 16 
that prevents the closed E2~Ub conformation. HHARI His234 would sterically clash with Ub 17 
in the “closed” E2~Ub, and similarly, His234 is incompatible with the “closed-like” E2~Ub 18 
adopted in the RCR complex. MYCBP2 complex RING (blue), E2 (mauve), Ub (gray), zinc 19 
(gray); HHARI complex RING1 (light blue), E2 (wheat) and zinc (light gray). 20 
 21 
 22 
Extended Data Fig. 8. The RCR-helix-turn-helix motif prevents binding of an open 23 
E2~Ub conjugate, UBE2L3 activity cannot be imparted by Lys96Ser mutation, and 24 
further mediator loop analysis. a, Superposition of ‘open’ conformation E2~Ub from a 25 
HECT E2~Ub complex (PDB 3JVZ) with the RCR E2~Ub complex. The open conformation 26 
in the HECT E2~Ub complex is incompatible with the observed RCR conformation as Ub is 27 
sterically blocked by the helix-turn-helix motif. HECT E2 (pink) and Ub (light gray) are 28 
displayed in cartoon representation. b, Despite introduction of the corresponding lysine residue 29 
into UBE2D3 abolishing its activity, we could not impart UBE2L3 activity by substitution of 30 
Lys96 to Ser, as found in UBE2D3. Blue squares and black circles correspond to experiments 31 
where E3 was added or withheld, respectively (n =3 independent experiments performed with 32 
identical purified proteins). c, The mediator loop has high sequence conservation across 33 
orthologues. The deletions in Drosophila and C. elegans relative to human MYCBP2 imply 34 
the Ub relay process is highly plastic. d, Deletion of mediator loop residue A4518 substantially 35 







Extended Data Figure 9. Relaxation of the E2 Ser94-RING Pro4438 interaction is 1 
crystallographically observed for RING-linked E3s (RBRs and RCR) relative to 2 
canonical RINGs. Interestingly, the Ser94-Pro4438 H-bond is highly conserved in solved E2-3 
RING structures but for canonical RING E3s an idealized geometry is observed (2.3-3.0 Å). 4 
For RBR E3s that undergo transthiolation, this H-bond distance is comparable to that observed 5 
for the RCR being ~0.4 Å longer. Thus, it would appear that relaxation of this H-bond may be 6 
a hallmark of RING-linked E3s but the mechanistic basis for this is not clear. a, Distances 7 
between E2 Ser94 (gamma oxygen) and E3 Pro (carbonyl oxygen) for MYCBP2 relative to 8 
canonical RING E3s. b, Alignment of the C-terminal portion of the RING including the 7th and 9 
8th zinc coordinating residues. The conserved proline that interacts with E2 serine 94 is shown 10 
in blue. Zinc coordinating residues are shown in red. The linchpin residue location is indicated 11 
with an asterisk. c, Distances between E2 Ser94 (gamma oxygen), or E2 Lys96 (epsilon amino 12 
nitrogen), and E3 Pro (carbonyl oxygen) for MYCBP2 relative to RBR E3s. d, Alignment of 13 
the c-terminal portion of the RING including the 7th and 8th zinc coordinating residues. The 14 
conserved proline that interacts with E2 serine 94 in MYCBP2 shown in blue. Zinc 15 
coordinating residues are shown in red. 16 
 17 
Extended Data Figure 10. Further characterization of Phr1C4629A/C4629A mouse line. a, 18 
Expression levels of Phr1/MYCBP2 in Phr1+/+ (WT), Phr1C4629A/+ (HET) and Phr1C4629A/C4629A 19 
(HOM) mouse embryonic fibroblasts (MEFs) and neuroblastoma SH-SY5Y cells (CRISPR 20 
KO and WT) (left). An alternative in-house antibody25 was also used to assess Phr1 expression 21 
levels across genotypes (right). b, Experimental work-flow used to generate activity-based 22 
 42 
proteomic data presented in Figure 5b. c, Extracted proteomes from MEF with indicated 1 
genotypes were treated with a maltose-binding protein (MBP)-tagged activity-based probe. 2 
MBP tagging was necessary to discern a gel shift upon MYCBP2/Phr1 (0.5 MDa) labelling. 3 
ABP labelling was selectively abolished in Phr1C4629A/C4629A MEFs consistent with the E3 ligase 4 
activity being disrupted. This experiment was carried out twice with similar results. d, 5 
NMNAT2 with a C-terminal HA-tag was transiently transfected into MEFs representing all 6 
three genotypes. This experiment was carried out once. e, The number of secondary branches 7 
(gray) between the primary branches (black) crossing the red dotted line were counted. 8 
Quantification of secondary axonal branches of the right phrenic nerve; n number per genotype 9 
are indicated in the figure (mean ±SEM; Kruskal-Wallis test followed by Dunn’s multiple 10 
comparison test). Asterisks indicate: * P ≤ 0.05. 11 
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